Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.
Gounder MM, Zer A, Tap WD, Salah S, Dickson MA, Gupta AA, Keohan ML, Loong HH, D'Angelo SP, Baker S, Condy M, Nyquist-Schultz K, Tanner L, Erinjeri JP, Jasmine FH, Friedlander S, Carlson R, Unger TJ, Saint-Martin JR, Rashal T, Ellis J, Kauffman M, Shacham S, Schwartz GK, Abdul Razak AR. Gounder MM, et al. Among authors: erinjeri jp. J Clin Oncol. 2016 Sep 10;34(26):3166-74. doi: 10.1200/JCO.2016.67.6346. Epub 2016 Jul 25. J Clin Oncol. 2016. PMID: 27458288 Free PMC article. Clinical Trial.
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Doyle A, Ancell K, Panageas KS, Bluth M, Hedvat C, Erinjeri J, Ambrosini G, Marr B, Abramson DH, Dickson MA, Wolchok JD, Chapman PB, Schwartz GK. Carvajal RD, et al. JAMA. 2014 Jun 18;311(23):2397-405. doi: 10.1001/jama.2014.6096. JAMA. 2014. PMID: 24938562 Free PMC article. Clinical Trial.
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone.
Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D'Angelica MI, Allen PJ, Erinjeri JP, Brody LA, O'Neill GP, Johnson KN, Garcia AR, Beattie C, Zhao B, Solomon SB, Schwartz LH, DeMatteo R, Abou-Alfa GK. Brown KT, et al. Among authors: erinjeri jp. J Clin Oncol. 2016 Jun 10;34(17):2046-53. doi: 10.1200/JCO.2015.64.0821. Epub 2016 Feb 1. J Clin Oncol. 2016. PMID: 26834067 Free PMC article. Clinical Trial.
Local Ablative Therapies to Metastatic Soft Tissue Sarcoma.
Gronchi A, Guadagnolo BA, Erinjeri JP. Gronchi A, et al. Among authors: erinjeri jp. Am Soc Clin Oncol Educ Book. 2016;35:e566-75. doi: 10.1200/EDBK_157450. Am Soc Clin Oncol Educ Book. 2016. PMID: 27249769 Free article. Review.
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.
D'Angelo SP, Shoushtari AN, Keohan ML, Dickson MA, Gounder MM, Chi P, Loo JK, Gaffney L, Schneider L, Patel Z, Erinjeri JP, Bluth MJ, Sjoberg A, Streicher H, Takebe N, Qin LX, Antonescu C, DeMatteo RP, Carvajal RD, Tap WD. D'Angelo SP, et al. Among authors: erinjeri jp. Clin Cancer Res. 2017 Jun 15;23(12):2972-2980. doi: 10.1158/1078-0432.CCR-16-2349. Epub 2016 Dec 22. Clin Cancer Res. 2017. PMID: 28007774 Free PMC article. Clinical Trial.
Reply to A. Braillon, M. Boulin et al, and J.-H. Zhong et al.
Brown KT, Do R, Gönen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D'Angelica MI, Allen PJ, Erinjeri JP, Brody LA, O'Neill GP, Johnson K, Garcia AR, Beattie CM, Zhao B, Solomon SB, Schwartz LH, DeMatteo RP, Abou-Alfa GK. Brown KT, et al. Among authors: erinjeri jp. J Clin Oncol. 2017 Jan 10;35(2):258-259. doi: 10.1200/JCO.2016.69.7961. Epub 2016 Oct 23. J Clin Oncol. 2017. PMID: 28056199 No abstract available.
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, Bialer P, Lacouture ME, Teitcher JB, Erinjeri JP, Katabi N, Fury MG, Hyman DM. Smyth LM, et al. Among authors: erinjeri jp. Invest New Drugs. 2017 Dec;35(6):742-750. doi: 10.1007/s10637-017-0445-0. Epub 2017 Mar 9. Invest New Drugs. 2017. PMID: 28281183 Free PMC article. Clinical Trial.
AKT Inhibition in Solid Tumors With AKT1 Mutations.
Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS. Hyman DM, et al. Among authors: erinjeri jp. J Clin Oncol. 2017 Jul 10;35(20):2251-2259. doi: 10.1200/JCO.2017.73.0143. Epub 2017 May 10. J Clin Oncol. 2017. PMID: 28489509 Free PMC article.
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.
Kelly CM, Antonescu CR, Bowler T, Munhoz R, Chi P, Dickson MA, Gounder MM, Keohan ML, Movva S, Dholakia R, Ahmad H, Biniakewitz M, Condy M, Phelan H, Callahan M, Wong P, Singer S, Ariyan C, Bartlett EK, Crago A, Yoon S, Hwang S, Erinjeri JP, Qin LX, Tap WD, D'Angelo SP. Kelly CM, et al. Among authors: erinjeri jp. JAMA Oncol. 2020 Mar 1;6(3):402-408. doi: 10.1001/jamaoncol.2019.6152. JAMA Oncol. 2020. PMID: 31971541 Free PMC article. Clinical Trial.
138 results